Premium
Effect of antioxidant probucol for preventing stent restenosis
Author(s) -
Kim Moo Hyun,
Cha Kwang Soo,
Han JinYeong,
Kim Hye Jin,
Kim Jong Seong
Publication year - 2002
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10346
Subject(s) - probucol , medicine , restenosis , premedication , aspirin , ticlopidine , cardiology , stent , coronary artery disease , antioxidant , surgery , urology , clopidogrel , cholesterol , biochemistry , chemistry
Probucol is a lipid‐lowering drug that has an antioxidant effect. The authors sought to investigate the effect of probucol on stent restenosis after the usual 3‐day pretreatment protocol. From March 1999 to August 2000, 78 patients (mean age, 56 ± 8; 49 male) with coronary artery disease who underwent coronary stenting were enrolled. After a diagnostic angiography was done, each eligible patient was randomized to either the probucol or the control group. Following the procedure, ticlopidine was administered for 1 month; aspirin and probucol continuously. Angiographic follow‐up was done in 81% (57/70) and angiographic restenosis was not different between the two groups (21% vs. 24%; P = 0.81). In conclusion, antioxidant probucol did not show a beneficial effect on stent restenosis with 3 days of premedication protocol. Cathet Cardiovasc Intervent 2002;57:424–428. © 2002 Wiley‐Liss, Inc.